Biochanin A improves insulin sensitivity and controls hyperglycemia in type 2 diabetes - 20/09/18
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
| pages | 9 |
| Iconographies | 11 |
| Vidéos | 0 |
| Autres | 0 |
Graphical abstract |
Highlights |
• | Biochanin A is an isoflavone presents in legume plants including Red clover and soy. |
• | Biochanin A reduces insulin resistance and improves insulin sensitivity. |
• | Biochanin A increases the expression of SIRT1 in pancreatic tissue. |
Abstract |
Biochanin A (5,7-Dihydroxy-4′-methoxyisoflavone) is an O-methylated isoflavone known for its anti-inflammatory, lipid lowering and anti-cancer activity. The current study was designed to find out antidiabetic efficacy of Biochanin A in type 2 diabetes in rats.
Induction of type 2 diabetes mellitus in experimental animals was carried out by manipulation of diet using high fat diet for fourteen days and then administration of streptozotocin at low dose of 35 mg/kg, i.p. The diabetic animals were treated with 10, 20 and 40 mg/kg of Biochanin A for 28 days. The effect of Biochanin A treatment in diabetic animals was evaluated by measuring changes in body weight, biochemical parameters, insulin sensitivity index, Homeostatic model assessment-Insulin resistance (HOMA-IR), oral glucose tolerance test, glycohaemoglobin and hepatic glycogen level. Changes in histopathological characteristics of pancreatic tissue were also evaluated after treatment with Biochanin A. Immunohistochemical analysis of pancreatic tissue was carried out for the expression of SIRT1.
The results showed that the selected doses of (10, 20 and 40 mg/kg) Biochanin A significantly decreased blood glucose (p < 0.001). The higher dose (40 mg/kg) of Biochanin A significantly reduced glucose tolerance (p < 0.001) in diabetic animals. Biochanin A treatment significantly reduced insulin resistance (p < 0.001) and improved inulin sensitivity (p < 0.01 for 10 mg/kg, 20 mg/kg, p < 0.001 for 40 mg/kg) at all selected dose levels. It also improved lipid profile significantly (p < 0.001) at lower, middle and higher dose level. Glycohaemoglobin formation was significantly decreased in diabetic animals (p < 0.001) after treatment with Biochanin A at all three dose levels. Liver glycogen level was also improved significantly after treatment with Biochanin A in diabetic animals at 20 mg/kg and 40 mg/kg dose level. Biochanin A at dose of 40 mg/kg increased SIRT1 expression in pancreatic tissue. In conclusion, Biochanin A has significant effect in type 2 diabetes mellitus which might be linked to its effects on SIRT1.
Le texte complet de cet article est disponible en PDF.Abbreviations : HOMA-IR, HDL, LDL, PPAR, MAP, OGTT, ISI, VLDL, NAD
Keywords : Biochanin A, Insulin resistance, Isoflavones, Type 2 diabetes mellitus, Hyperglycemia, SIRT1
Plan
Vol 107
P. 1119-1127 - novembre 2018 Retour au numéro
Article précédent
- Resveratrol analogue, trans-4,4′-dihydroxystilbene (DHS), inhibits melanoma tumor growth and suppresses its metastatic colonization in lungs
- Bhaskar Saha, Ganesh B. Pai, Mahesh Subramanian, Pooja Gupta, Mrityunjay Tyagi, Birija Sankar Patro, Subrata Chattopadhyay
- Eriodictyol inhibits IL-1β-induced inflammatory response in human osteoarthritis chondrocytes
- Yongsheng Wang, You Chen, Ying Chen, Bingkang Zhou, Xiaowei Shan, Guangjie Yang
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?